Pliant Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PLRX Nasdaq 2830 pliantrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pliant Therapeutics, Inc.

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA) - Oct 20th, 2026 6:30 am
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - Oct 19th, 2026 2:05 pm
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - Sep 30th, 2026 2:10 pm
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - Aug 18th, 2026 6:30 am
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Aug 11th, 2026 2:05 pm
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors - Jul 13th, 2026 6:30 am
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - May 11th, 2026 2:05 pm
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - May 6th, 2026 6:30 am
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Apr 30th, 2026 6:30 am
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting - Apr 18th, 2026 11:31 am
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Mar 18th, 2026 7:00 am
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - Mar 11th, 2026 2:05 pm
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Mar 1st, 2026 8:39 am
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - Feb 23rd, 2026 6:00 am
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Nov 6th, 2025 2:05 pm